• Amylyx Pharmaceuticals recently saw increased analyst attention after the FDA approved its lead therapy AMX0035 for amyotrophic lateral sclerosis, reinforcing its focus on rare neurological diseases.
• This wave of analyst optimism underscores how regulatory progress on AMX0035 may influence expectations for Amylyx’s broader pipeline and long-term business potential.
• We’ll now explore how this renewed analyst confidence following AMX0035’s FDA approval could influence Amylyx Pharmaceuticals’ existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Amylyx Pharmaceuticals Investment Narrative Recap

To own Amylyx Pharmaceuticals, you need to believe avexitide can become the first approved treatment for post bariatric hypoglycemia while the broader rare disease pipeline matures. In the near term, the key catalyst is still LUCIDITY Phase III data in Q3 2026, and the biggest risk remains an unfavorable readout that prolongs losses. The recent analyst optimism after AMX0035’s FDA approval supports sentiment but does not materially change that core risk reward equation.

The most relevant update alongside this analyst reaction is the completion of enrollment in the LUCIDITY trial, with 78 PBH patients now randomized and dosed. With topline data expected in Q3 2026, investors can connect today’s enthusiasm around AMX0035 and ALS to the clearer timetable for avexitide, which still looks like the pivotal event for Amylyx’s path to its first new revenue stream and any future diversification beyond PBH.

Yet beneath the excitement around AMX0035’s approval, investors should be aware that LUCIDITY’s single pivotal design means...

Amylyx Pharmaceuticals’ narrative projects $107.8 million in revenue and $23.1 million in earnings by 2029. This implies an earnings increase of about $167.8 million from -$144.7 million today.

Uncover how Amylyx Pharmaceuticals' forecasts yield a $22.20 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were modeling revenue of about US$459.0 million by 2029, which contrasts sharply with the concentration risk if avexitide or follow on GLP 1 programs stumble, reminding you that opinions can differ widely and may shift as AMX0035’s approval and upcoming data are digested.

Explore 3 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• Outshine the giants: these 20 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.